Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838551 · ClinicalTrials.gov registry record · Phase 3
Treatment for Endogenous Cushing's Syndrome
A Phase 3 study of Endogenous Cushing's Syndrome, sponsored by Cortendo AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT01838551 is a Phase 3 study of Endogenous Cushing's Syndrome that has completed, run by Cortendo AB. The registered enrollment target is 94 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01838551, a Phase 3 study of Endogenous Cushing's Syndrome, has completed, sponsored by Cortendo AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and to evaluate the range of effective doses in subjects with various levels of hypercortisolism.
Conditions Studied
Interventions
- DRUG Levoketoconazole
Study Locations (20)
Other
- University Hospitals Leuven Department of Endocrinology - Leuven
- University Specialized Hospital for Active Treatment in Endocrinology (USHATE) - Sofia
- Vseobecna fakultni nemocnice v Praze - III. Interni klinika VFN a 1. LF UK - Prague
- Aarhus University Hospital - Aarhus
- Rigshospitalet,Copenhagen University Hospital - Copenhagen
- Hôpital de la CONCEPTION, Service d'Endocrinologie, Diabète et Maladies Métaboliques - Marseille
- Med Clinic I - University of Lueback - Lübeck
- Bnail Zion Medical Center Institute of Endocrinology & Metabolism - Haifa
- Institute of Endocrinology & Metabolism, Rabin Medical Center - Petah Tikva
- Sourasky Medical Center, Endocrinology & Metabolism - Tel Aviv
California
- UCLA School of Medicine - Los Angeles
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Medical Center - Ann Arbor
New Mexico
- University of New Mexico HSC - Albuquerque
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838551
The ClinicalTrials.gov registry entry for NCT01838551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cortendo AB, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endogenous Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Levoketoconazole is the first listed.
NCT01838551 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01838551 about?
NCT01838551 is a clinical study titled "Treatment for Endogenous Cushing's Syndrome". The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and to evaluate the range of effective doses in subjects with various level...
What is the current status of trial NCT01838551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2014-08. Estimated completion is 2018-11.
What conditions does trial NCT01838551 study?
This clinical trial studies the following conditions: Endogenous Cushing's Syndrome.
What interventions are being tested in trial NCT01838551?
The interventions under investigation include: Levoketoconazole (DRUG).
Who is sponsoring clinical trial NCT01838551?
This trial is sponsored by Cortendo AB, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01838551 being conducted?
This trial has 20 study locations across California, Maryland, Massachusetts, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endogenous Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.